Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 9 for:    antroquinonol

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02719028
Recruitment Status : Completed
First Posted : March 25, 2016
Results First Posted : December 20, 2019
Last Update Posted : January 2, 2020
Sponsor:
Information provided by (Responsible Party):
Golden Biotechnology Corporation

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition Hyperlipidemias
Interventions Drug: Antroquinonol
Drug: placebo
Enrollment 120
Recruitment Details A multi-center, phase II, prospective, double blind, randomized, placebo-controlled trial, recruiting from 23-Jun-2016 to 30-Aug-2018 6 sites are NTUniversity Hospital; CMU Hospital; NCKU Hospital; Taipei VG Hospital; FEM Hospital; CGM Hospital, Linkou branch;
Pre-assignment Details total treatment period: 16 weeks including a 2-week screening visit, a 12-week study treatment, and a 2-week follow-up
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Period Title: Overall Study
Started 30 30 30 30
Completed 28 28 24 20
Not Completed 2 2 6 10
Reason Not Completed
Adverse Event             2             1             4             8
Physician Decision             0             1             1             1
Use of prohibited medication             0             0             1             0
Protocol Violation             0             0             0             1
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO Total
Hide Arm/Group Description

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Total of all reporting groups
Overall Number of Baseline Participants 30 30 30 30 120
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 30 participants 30 participants 30 participants 30 participants 120 participants
48.2  (15.12) 53.3  (13.18) 48.9  (10.32) 52.5  (9.98) 50.70  (12.37)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 30 participants 30 participants 30 participants 30 participants 120 participants
Female
12
  40.0%
10
  33.3%
5
  16.7%
8
  26.7%
35
  29.2%
Male
18
  60.0%
20
  66.7%
25
  83.3%
22
  73.3%
85
  70.8%
Race (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 30 participants 30 participants 30 participants 30 participants 120 participants
American Indian or Alaska Native
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Asian
30
 100.0%
30
 100.0%
30
 100.0%
30
 100.0%
120
 100.0%
Native Hawaiian or Other Pacific Islander
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Black or African American
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
White
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
More than one race
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Unknown or Not Reported
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
Taiwan Number Analyzed 30 participants 30 participants 30 participants 30 participants 120 participants
30 30 30 30 120
BMI  
Mean (Standard Deviation)
Unit of measure:  Kg/m^2
Number Analyzed 30 participants 30 participants 30 participants 30 participants 120 participants
28.4  (4.71) 27.2  (3.80) 28.4  (5.41) 26.8  (3.72) 27.68  (4.36)
1.Primary Outcome
Title TG Change (mg/dL )
Hide Description value at 12 weeks minus value at baseline
Time Frame 12 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
Per-protocol population
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description:

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Overall Number of Participants Analyzed 28 28 22 20
Median (95% Confidence Interval)
Unit of Measure: percentage of change
-9.2
(-17.97 to 12.20)
14.6
(3.48 to 40.8)
-4.2
(-15.68 to 15.80)
-1.3
(-13.01 to 15.17)
2.Secondary Outcome
Title LDL& HDL (mg/dL)
Hide Description value at 12 weeks minus value at baseline of PP pupulation in HDL/LDL ratio.
Time Frame 12 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description:

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Overall Number of Participants Analyzed 28 28 22 20
Mean (Standard Deviation)
Unit of Measure: percentage of change
2.4  (21.73) 5.1  (23.02) -1.1  (15.51) 0.3  (13.98)
3.Secondary Outcome
Title Non-invasive Arterial Stiffness Measurement
Hide Description To evaluate the effect of Antroquinonol via a non-invasive arterial stiffness measurement.
Time Frame 12 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
Per-protocol population
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description:

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Overall Number of Participants Analyzed 28 28 22 20
Mean (Standard Deviation)
Unit of Measure: percentage of change
3.1  (9.58) 0.0  (13.80) -3.3  (10.38) 2.8  (9.84)
4.Secondary Outcome
Title Fatty Liver
Hide Description To evaluate the recover fatty liver effect of Antroquinonol on patients who with fatty liver by Investigator
Time Frame 12 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
Only Per-protocol population subjects with abnormal liver attenuation at baseline subjected to follow-up after 12 weeks
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description:

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Overall Number of Participants Analyzed 15 13 12 11
Measure Type: Count of Participants
Unit of Measure: Participants
0
   0.0%
4
  30.8%
1
   8.3%
1
   9.1%
Time Frame 16 weeks start from Screening visit to follow up visit. The mean duration of dosing was 81.4 days in the placebo group, 81.3 days in the antroquinonol 50 mg group, 75.6 days in the antroquinonol 100 mg group, and 65.0 days in the antroquinonol 150 mg group.
Adverse Event Reporting Description there are few patients had more than one AE during the study
 
Arm/Group Title Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Hide Arm/Group Description

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (Placebo) 3 capsules once a day.

placebo: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (1 capsule of antroquinnonol 50mg and 2 capsules of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (2 capsules of antroquinnonol 50mg and 1 capsule of Placebo) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg ) 3 capsules once a day.

Antroquinonol: Antroquinonol will be provided as capsules of 50 mg

All-Cause Mortality
Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   8/14 (57.14%)      8/13 (61.54%)      12/19 (63.16%)      17/18 (94.44%)    
Hide Serious Adverse Events
Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   0/14 (0.00%)      0/13 (0.00%)      1/19 (5.26%)      0/18 (0.00%)    
Renal and urinary disorders         
ureterolithiasis and urinary tract disorder  1 [1]  0/14 (0.00%)  0 0/13 (0.00%)  0 1/19 (5.26%)  2 0/18 (0.00%)  0
1
Term from vocabulary, MedDRA v20.0
Indicates events were collected by systematic assessment
[1]
one patient has two SAEs: ureterolithiasis and urinary tract disorder. Both are not related to Antroquinonol
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Placebo Antroquinonol 50 mg PO Antroquinonol 100 mg PO Antroquinonol 150 mg PO
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   8/14 (57.14%)      8/13 (61.54%)      12/19 (63.16%)      17/18 (94.44%)    
Gastrointestinal disorders         
Diarrhoea  1  4/14 (28.57%)  4 8/13 (61.54%)  8 9/19 (47.37%)  9 13/18 (72.22%)  13
Nausea  1  0/14 (0.00%)  0 0/13 (0.00%)  0 3/19 (15.79%)  3 3/18 (16.67%)  3
Vomiting  1  0/14 (0.00%)  0 1/13 (7.69%)  1 0/19 (0.00%)  0 3/18 (16.67%)  3
Hepatobiliary disorders         
Hepatic function abnormal  1  2/14 (14.29%)  2 3/13 (23.08%)  3 0/19 (0.00%)  0 1/18 (5.56%)  1
Infections and infestations         
Viral upper respiratory tract infection  1  2/14 (14.29%)  2 0/13 (0.00%)  0 0/19 (0.00%)  0 0/18 (0.00%)  0
1
Term from vocabulary, MedDRA v20.0
Indicates events were collected by systematic assessment
Additional study with larger sample size is warranted to confirm antroquinonol in treating hyperlipidemia, arterial stiffness, and fatty liver.
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Howard Cheng
Organization: Golden Biotechnology Corp
Phone: +886-2-28086006
EMail: howard@goldenbiotech.com
Layout table for additonal information
Responsible Party: Golden Biotechnology Corporation
ClinicalTrials.gov Identifier: NCT02719028    
Other Study ID Numbers: GHLIP-2-001
First Submitted: March 10, 2016
First Posted: March 25, 2016
Results First Submitted: October 16, 2019
Results First Posted: December 20, 2019
Last Update Posted: January 2, 2020